Agilent s Short-Term Plan to Grow Life Sciences Arm May Not Include Big Buy | GenomeWeb

In the midst of selling off its semiconductor business to private equity firms Kohlberg Kravis Roberts and Silver Lake Partners for $2.66 billion (see BioCommerce Week 8/18/2005), Agilent officials suggested this week that the firm is unlikely to pursue a large acquisition to bolster its life sciences business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.